Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

OncoPep

Status and phase: Not yet enrolling; Phase 2

Conditions: Metastatic Triple-Negative Breast Carcinoma

Treatments: Drug: PVX-410

Study type: Interventional

Funder types: Industry

Identifiers

NCT04634747

2020-001

Details and patient eligibility

About

Evaluating the combination of the investigational, multi-peptide cancer vaccine PVX-410 in combination with pembrolizumab and chemotherapy in treatment naive patients with metastatic, triple negative breast cancer who are PDL1 and HLA A2 positive.

Enrollment: 53 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HLA A2 Positive PDL1 Positive Treatment naive, triple negative breast cancer

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

53 participants in 1 patient group

PVX-410/pembrolizumab/chemotherapy

Experimental group

Treatment:

Drug: PVX-410